Abstract
The therapeutic potential of mesenchymal stem/stromal cells (MSC) has triggered the need for high cell doses in a vast number of clinical applications. This demand requires the development of good manufacturing practices (GMP)-compliant ex vivo expansion protocols that should be effective to deliver a robust and reproducible supply of clinical-grade cells in a safe and cost-effective manner. Controlled stirred-tank bioreactor systems under xenogeneic (xeno)-free culture conditions offer ideal settings to develop and optimize cell manufacturing to meet the standards and needs of human MSC for cellular therapies. Herein we describe two microcarrier-based stirred culture systems using spinner flasks and controlled stirred-tank bioreactors under xeno-free conditions for the efficient ex vivo expansion of human bone marrow and adipose tissue-derived MSC.
Key words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Parekkadan B, Milwid JM (2010) Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 12:87–117
Trounson A, Thakar RG, Lomax G et al (2011) Clinical trials for stem cell therapies. BMC Med. doi:10.1186/1741-7015-9-52
da Silva Meirelles L, Chagastelles PC, Nardi NB (2006) Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119:2204–2213
Pittenger MF, Mackay AM, Beck SC et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143–147
Atoui R, Chiu RC (2012) Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns. Stem Cells Transl Med 1:200–205
Dittmar T, Entschladen F (2013) Migratory properties of mesenchymal stem cells. Adv Biochem Eng Biotechnol 129:117–136
Singer NG, Caplan AI (2011) Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 6:457–478
Migliaccio G, Pintus C (2013) Role of the EU framework in regulation of stem cell-based products. Adv Biochem Eng Biotechnol 130:287–299
Bieback K, Kinzebach S, Karagianni M (2011) Translating research into clinical scale manufacturing of mesenchymal stromal cells. Stem Cells Int 2010:193519
Thirumala S, Goebel WS, Woods EJ (2013) Manufacturing and banking of mesenchymal stem cells. Expert Opin Biol Ther 13:673–691
Bieback K, Schallmoser K, Kluter H et al (2008) Clinical protocols for the isolation and expansion of mesenchymal stromal cells. Transfus Med Hemother 35:286–294
Kirouac DC, Zandstra PW (2008) The systematic production of cells for cell therapies. Cell Stem Cell 3:369–381
Rodrigues CA, Fernandes TG, Diogo MM et al (2011) Stem cell cultivation in bioreactors. Biotechnol Adv 29:815–829
Dos Santos F, Andrade PZ, Silva CL et al (2013) Scaling-up ex vivo expansion of mesenchymal stem/stromal cells for cellular therapies. In: Chase LG, Vemuri MC (eds) Mesenchymal stem cell therapy. Humana Press, New York, pp 1–14
Eibes G, dos Santos F, Andrade PZ et al (2010) Maximizing the ex vivo expansion of human mesenchymal stem cells using a microcarrier-based stirred culture system. J Biotechnol 146:194–197
Dos Santos F, Andrade PZ, Abecasis MM et al (2011) Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions. Tissue Eng Part C Methods 17:1201–1210
Schop D, van Dijkhuizen-Radersma R, Borgart E et al (2010) Expansion of human mesenchymal stromal cells on microcarriers: growth and metabolism. J Tissue Eng Regen Med 4:131–140
Yuan Y, Kallos MS, Hunter C et al (2014) Improved expansion of human bone marrow-derived mesenchymal stem cells in microcarrier-based suspension culture. J Tissue Eng Regen Med 8:210–225
Rafiq QA, Brosnan KM, Coopman K et al (2013) Culture of human mesenchymal stem cells on microcarriers in a 5 l stirred-tank bioreactor. Biotechnol Lett 35:1233–1245
Hewitt CJ, Lee K, Nienow AW et al (2011) Expansion of human mesenchymal stem cells on microcarriers. Biotechnol Lett 33:2325–2335
Dos Santos F, Campbell A, Fernandes-Platzgummer A et al (2014) A xenogeneic-free bioreactor system for the clinical-scale expansion of human mesenchymal stem/stromal cells. Biotechnol Bioeng 111:1116–1127
Hupfeld J, Gorr IH, Schwald C et al (2014) Modulation of mesenchymal stromal cell characteristics by microcarrier culture in bioreactors. Biotechnol Bioeng. doi:10.1002/bit.25281
Miwa H, Hashimoto Y, Tensho K et al (2012) Xeno-free proliferation of human bone marrow mesenchymal stem cells. Cytotechnology 64:301–308
Fekete N, Rojewski MT, Furst D et al (2012) GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One 7:e43255
Kinzebach S, Bieback K (2013) Expansion of mesenchymal stem/stromal cells under xenogeneic-free culture conditions. Adv Biochem Eng Biotechnol 129:33–57
Lindroos B, Boucher S, Chase L et al (2009) Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro. Cytotherapy 11:958–972
Gimble J, Guilak F (2003) Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy 5:362–369
Chase LG, Yang S, Zachar V et al (2012) Development and characterization of a clinically compliant xeno-free culture medium in good manufacturing practice for human multipotent mesenchymal stem cells. Stem Cells Transl Med 1:750–758
Bernardo ME, Avanzini MA, Perotti C et al (2007) Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol 211:121–130
Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317
Carmelo JG (2013) Optimizing the production of human mesenchymal stem/stromal cells in xeno-free microcarrier-based reactor systems. MSc Dissertation, Instituto Superior Técnico, Universidade de Lisboa, Lisboa
Acknowledgments
The authors greatly acknowledge Jeffrey M. Gimble, M.D. (Center for Stem Cell Research and Regenerative Medicine, Tulane University, New Orleans, Louisiana, USA) for kindly providing the human adipose-derived stem/stromal cells. The authors also thank the financial support from Fundação para a Ciência e a Tecnologia (FCT), Portugal, through iBB - Institute for Bioengineering and Biosciences under the project UID/BIO/04565/2013 and Programa Operacional Regional de Lisboa 2020 (Project N. 007317), projects PTDC/EQU-EQU/114231/2009 and HMSP-ICT/0001/2011 and grant SFRH/BPD/82062/2011 (awarded to AFP).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Fernandes-Platzgummer, A., Carmelo, J.G., da Silva, C.L., Cabral, J.M.S. (2016). Clinical-Grade Manufacturing of Therapeutic Human Mesenchymal Stem/Stromal Cells in Microcarrier-Based Culture Systems. In: Gnecchi, M. (eds) Mesenchymal Stem Cells. Methods in Molecular Biology, vol 1416. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3584-0_22
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3584-0_22
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3582-6
Online ISBN: 978-1-4939-3584-0
eBook Packages: Springer Protocols